Organovo Corp (ONVO): Price/Earnings to Growth Multiple

Symbol and logo of brand Organovo Corp (ONVO)

Organovo Holdings, Inc. (ONVO) is strengthening its position by creating 3D liver models for pharma behemoths based on its patents. The P/E valuation relative to business expansion rates confirms market interest, where 0.00 captures the magnitude of this parameter. An ethical approach reduces animal testing, while the use of cloud computing minimizes capital expenditures, maintaining full control over the company's unique developments.

ONVO organovo.com Price/Earnings to Growth Multiple (07/04/2022 - 04/24/2025)

Analytical breakdowns for Organovo (ONVO)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:ONVO - Organovo Corp
Signature product of organovo.com

Organovo Holdings, Inc. (ONVO) development in 3D bioprinting of tissues requires colossal investments, making the cost of each unit of earnings growth a key valuation parameter. The P/E ratio relative to growth rates, reflected in the PEG investment attractiveness indicator, determines whether the market is overpaying for the biotech's future progress or if the asset is undervalued. A value below one signals "rocket" potential, provided the low level is not driven by critical business risks.

Competitors of Organovo Holdings, Inc.

ASND (Ascendis) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio madrigalpharma.com MDGL|CORT - Price/Earnings to Growth Multiple|Rhythm Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Akero Therapeutics Inc|MTSR (Metsera) - Price/Earnings to Growth Multiple|MLTX: Company Value to Earnings Growth Ratio|CRNX (Crinetics Corp) - PEG Multiple|PEG Multiple NewAmsterdam Pharma|PEG Multiple SLNO|Price/Earnings to Growth Ratio FOLD (Amicus Therapeutics Inc)|Price/Earnings to Growth Ratio 89bio.com ETNB|Agios Corp (AGIO) - Price to Earnings Adjusted for Growth Rate|GPCR - Price/Earnings to Growth Ratio|MDXG: Price/Earnings to Growth Ratio|RZLT: PEG Multiple|LXRX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio MBX Corp|Price/Earnings to Growth Multiple Altimmune Corp (ALT)|Price/Earnings to Growth Ratio aardvarktherapeutics.com (AARD)|Price/Earnings to Growth Multiple sagimet.com SGMT|PEG Multiple BIOA (BioAge)|Biomea Fusion - Price/Earnings to Growth Ratio|QNCX: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio GUTS (Fractyl)|VTVT (vTv Therapeutics, Inc.) - Price/Earnings to Growth Multiple|Agape ATP Corp. (ATPC) - PEG Multiple|Price/Earnings to Growth Ratio pluri-biotech.com|Price/Earnings to Growth Ratio SYBX|PEG Multiple LPCN|Matinas BioPharma Holdings - Growth-Adjusted P/E Ratio|PEG Multiple SPRB (sprucebiosciences.com)|Company Value to Earnings Growth Ratio GLTO (galecto.com)|CTCX - Price/Earnings to Growth Ratio|Market Cap to Earnings and Growth Ratio LUMO|Radius Health (RDUS) - Price/Earnings to Growth Ratio